<DOC>
	<DOCNO>NCT00597428</DOCNO>
	<brief_summary>The primary purpose study evaluate efficacy safety lubiprostone administration patient opioid-induced bowel dysfunction ( OBD ) .</brief_summary>
	<brief_title>Opioid-induced Bowel Dysfunction Pivotal Assessment Lubiprostone</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Consistent treatment chronic , noncancerrelated pain full agonist opioid least 30 day prior screen . Diagnosis opioidinduced bowel dysfunction confirm screening period . If patient history chronic constipation , condition must exacerbate initiation opioid treatment . Use prescribed overthecounter ( OTC ) medication affect gastrointestinal motility ( opioid therapy ) must discontinue study . If treat clinical depression selective serotonin reuptake inhibitor ( SSRIs ) , serotoninnorepinephrine reuptake inhibitor ( SNRIs ) , monoamine oxidase ( MAO ) inhibitor , treatment must stable dose least 30 day prior screen . Use laxative stool softener ( exception approve rescue medication ) must discontinue study . Opioid dose adjustment ( +/ 30 % ) , and/or change opioid agent route administration within 30 day screen . Nonambulatory patient , unable eat/drink , take oral medication , hold oral medication due vomit . Treatment opioid therapy cancerrelated pain , abdominal pain , scleroderma , and/or management drug addiction . Patient treat cancer past 5 year ( exception localize basal cell , squamous cell skin cancer , situ cancer resect ) . Gastrointestinal abdominal surgical procedure within 90 day prior screen . Female patient childbearing potential unable/unwilling use protocolspecified method ( ) birth control and/or pregnant , nursing , plan become pregnant nurse study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>